Announcement of The Consolidated Financial Report for The 2nd Quarter of Year 2023
2023.8.10
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2023/08/10 | Time of announcement | 18:02:54 |
| Subject | Announcement of The Consolidated Financial Report for The 2nd Quarter of Year 2023 | ||||
| Date of events | 2022/08/10 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2023/08/10 2.Date of the audit committee approved:2023/08/10 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2023/01/01~2023/06/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):2,427,895 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):1,467,147 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):579,382 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):686,730 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):546,336 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):547,374 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):2.20 11.Total assets end of the period (thousand NTD):9,635,312 12.Total liabilities end of the period (thousand NTD):3,688,297 13.Equity attributable to owners of parent end of the period (thousand NTD):5,384,747 14.Any other matters that need to be specified:None |
||||